SCHEMBL342672

SCHEMBL342672

CC(C=O)(CO)Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45
CYP2C19 P33261 3/20 0.44
CYP3A4 P08684 3/20 0.44
CYP2C9 P11712 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 3/20 0.42
CYP2D6 P10635 2/20 0.42
TRPA1 O75762 1/20 0.42
HIF1A Q16665 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FDPS P14324 1/20 0.40
CYP1A2 P05177 2/20 0.39
CTSK P43235 1/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ALOX15 P16050 1/20 0.39
SCN1A P35498 1/20 0.39
SCN2A Q99250 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28416740 0.88 TAAR1 (0.52) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9
SCHEMBL3367884 0.83 SLC6A2 (0.44) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9
SCHEMBL6792841 0.82 SLC6A2 (0.47) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9
SCHEMBL26093098 0.79 SLC6A2 (0.44) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9
SCHEMBL26093126 0.79 SLC6A2 (0.44) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9
SCHEMBL18398061 0.78 TRPA1 (0.43) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9
SCHEMBL624141 0.77 CTSK (0.45) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9
SCHEMBL2314314 0.76 SLC6A2 (0.48) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9
SCHEMBL28806779 0.76 SLC6A2 (0.48) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9
SCHEMBL2516872 0.76 FDPS (0.47) SLC6A2TAAR1CYP2C19CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421345-B2 Polyimines and uses thereof BOSTIK SA (FR) 2025-09-23 US disclosed
EP-4077273-B1 ALDIMINES AND USES THEREOF BOSTIK SA (FR) 2025-04-02 EP disclosed
EP-4077446-B1 POLYIMINES AND USES THEREOF BOSTIK SA (FR) 2023-08-23 EP disclosed
EP-3484898-B1 METHOD OF STABILIZING IMINO-FUNCTIONAL SILANE MOMENTIVE PERFORMANCE MAT INC (US) 2023-06-28 EP disclosed
US-20230044535-A1 POLYIMINES AND USES THEREOF BOSTIK SA (FR) 2023-02-09 US disclosed
EP-4077446-A1 POLYIMINES AND USES THEREOF Bostik SA (FR) 2022-10-26 EP disclosed
EP-4077273-A1 ALDIMINES AND USES THEREOF Bostik SA (FR) 2022-10-26 EP disclosed
EP-4053134-A1 METHOD OF STABILIZING IMINO-FUNCTIONAL SILANE Momentive Performance Materials Inc. (US) 2022-09-07 EP disclosed
CN-109563111-B Method for stabilizing imino-functional silanes 莫门蒂夫性能材料股份有限公司 2022-04-12 CN disclosed
US-11230563-B2 Method of stabilizing imino-functional silane MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2022-01-25 US disclosed
EP-1834971-A1 Moisture curable polyurethane composition having good low temperature properties Sika Technology AG (CH) 2007-09-19 EP disclosed
US-20070129522-A1 Two-component polyurethane compound exhibiting a high early strength SIKA TECHNOLOGY AG (CH) 2007-06-07 US disclosed
CN-1894263-A Aldiminoalkylsilanes SIKA TECHNOLOGY AG (CH) 2007-01-10 CN disclosed
CN-1882627-A Two-component polyurethane compositions having high early strength SIKA TECHNOLOGY AG (CH) 2006-12-20 CN disclosed
EP-1697385-A2 ALDIMINOALKYLSILANES Sika Technology AG (CH) 2006-09-06 EP disclosed
EP-1678230-A1 TWO-COMPONENT POLYURITHANE COMPOUND EXHIBITING A HIGH EARLY STRENGTH Sika Technology AG (CH) 2006-07-12 EP disclosed
WO-2005058921-A2 ALDIMINOALKYLSILANES SIKA TECHNOLOGY AG (CH) 2005-06-30 WO disclosed
EP-1544204-A1 Aldiminoalkylsilanes Sika Technology AG (CH) 2005-06-22 EP disclosed
WO-2005037885-A1 TWO-COMPONENT POLYURITHANE COMPOUND EXHIBITING A HIGH EARLY STRENGTH SIKA TECHNOLOGY AG (CH) 2005-04-28 WO disclosed
EP-1524282-A1 Two-component polyurethane composition having high early strength Sika Technology AG (CH) 2005-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230563-B2 Method of stabilizing imino-functional silane INF2, RNF168, BOLA2; BOLA2B SLC6A2 3248/4885TAAR1 1962/4885CYP2C19 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.